Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors
Authors:
- Hemin NieHNHemin Nie
- Yilong FuYFYilong Fu
- Chi-Hwa WangCWChi-Hwa Wang
- 1 November 2010
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 31 (33) , 8732-8740
Abstract
No abstract availableKeywords
Funding Information
- Agency for Science, Technology and Research
- National University of Singapore (BMRC/07/1/21/19/508, R279-000-257-731)
- Biomedical Research Council
This publication has 31 references indexed in Scilit:
- Lysine-based peptide-functionalized PLGA foams for controlled DNA deliveryJournal of Controlled Release, 2009
- Designed Fabrication of a Multifunctional Polymer Nanomedical Platform for Simultaneous Cancer‐ Targeted Imaging and Magnetically Guided Drug DeliveryAdvanced Materials, 2008
- Interstitial Docetaxel (Taxotere), Carmustine and Combined Interstitial Therapy: a Novel Treatment for Experimental Malignant GliomaJournal of Neuro-Oncology, 2006
- In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogelsJournal of Controlled Release, 2005
- Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naïve and Paclitaxel-Pretreated Human Breast Xenograft TumorsClinical Cancer Research, 2004
- Population pharmacokinetics of low-dose paclitaxel in patients with brain tumorsAnti-Cancer Drugs, 2003
- Cremophor ELEuropean Journal of Cancer, 2001
- Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1999
- Cytotoxicity of taxol in vitro against human and rat malignant brain tumorsCancer Chemotherapy and Pharmacology, 1994
- LONG TERM CULTURE OF NORMAL AND NEOPLASTIC HUMAN GLIAActa Pathologica Microbiologica Scandinavica, 1968